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Abstract The interaction of heparin with heparin binding
growth-associated molecule (HB-GAM) was studied using
isothermal titration calorimetry (ITC) and surface plasmon
resonance (SPR). ITC studies showed that, in solution, heparin
bound HB-GAM with a vH of 330 kcal/mole corresponding to a
dissociation constant (Kd) of 460 nM. The stoichiometry of
interaction was 3 moles of HB-GAM per mole of heparin,
corresponding to a minimum heparin binding site for HB-GAM
of 12^16 saccharide residues. Kinetic measurements of heparin
interaction with HB-GAM made by SPR afforded a Kd of 4 nM,
suggesting considerably tighter binding when HB-GAM was
immobilized on a surface. Affinity chromatography of a sized
mixture of heparin oligosaccharides, having a degree of
polymerization (dp) of s 14 saccharide units, on HB-GAM-
Sepharose demonstrated that oligosaccharides having more than
18 saccharide residues showed the tightest interaction.
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1. Introduction
Heparin binding growth-associated molecule (HB-GAM),
also known as pleiotrophin, is a secretory extracellular ma-
trix-associated protein. It is an 18 kDa protein, rich in basic
amino acids, and of its 136 residues, 20.6% are lysine and
3.7% are arginine. These basic residues are clustered in two
discrete domains at the protein’s N-terminus and C-terminus
[1]. HB-GAM is found at high level in developing rat brains
[1] and at developing neuromuscular junctions [2]. The HB-
GAM sequence is highly conserved across species [3] and
shows about 50% homology to midkine [4].
HB-GAM enhances neurite outgrowth [5^10]. While HB-
GAM appears to have no mitogenic activity [10], it is involved
in providing extracellular tracts to guide neurites in the devel-
oping brain [11,12]. HB-GAM has also been shown to induce
proliferation arrest in limb development and is also involved
in muscle development [13].
N-syndecan (Syndecan-3) has been suggested to be the HB-
GAM receptor. This heparan sulfate proteoglycan binds HB-
GAM with high a⁄nity (Kd of 0.6 nM) and mediates neurite
outgrowth-promoting signal from growing neurites [11]. HB-
GAM and N-syndecan are also co-expressed in developing rat
brain [4]. The speci¢city of glycosaminoglycans on this inter-
action, investigated using a neurite outgrowth inhibition cell
assay system [14], demonstrated that heparin and heparan
sulfate showed activity while chondroitin sulfate and derma-
tan sulfate were inactive. Furthermore, the inhibitory e¡ects
of heparin were lost on 2-O-desulfation. Heparin oligosac-
charides having a degree of polymerization (dp) of 10 were
required for inhibition of HB-GAM induced neurite out-
growth with an optimal activity observed at dp 18. This ac-
tivity also correlated with the binding activity of these oligo-
saccharide fractions with HB-GAM. Recently, chondroitin
sulfate brain proteoglycans, phosphacan [15,16] and neurocan
[16], have also been shown to bind HB-GAM with high a⁄n-
ity.
The current study was undertaken to examine the thermo-
dynamics and kinetics of heparin binding to HB-GAM and to
further establish both the minimum and optimal size of the
binding domain in heparin for HB-GAM.
2. Materials and methods
Porcine intestinal mucosal heparin (Mr = 14 000) was obtained from
Celsus Laboratories (Cincinnati, OH, USA). Recombinant HB-GAM
was prepared using a baculovirus expression system and puri¢ed to
apparent homogeneity [11]. Heparin lyase I (heparinase I, EC 4.2.2.7)
and N-hydroxysuccinimidyl (NHS)-activated HiTrap column were
from Sigma Chemical (St. Louis, MO, USA). N-hydroxysuccinimide
and N-ethyl-NP-(dimethyaminopropyl) carbodiimide were from Phar-
macia (Uppsala, Sweden). Ethanolamine was from Fisher Chemical
(Fair Lawn, NJ, USA). 2H2O (99.96 atom %) was from Isotec Inc.
(Miamisburg, OH, USA). Dialysis tubing was purchased from Spec-
trum Laboratory Products (Houston, TX, USA). All spectrophoto-
metric measurements were carried out on a Shimadzu model UV-
21001 PC UV-vis spectrophotometer. Conductivity was determined
using a CDM 230 conductivity meter from radiometer (Copenhagen,
Denmark). Isothermal titration calorimetry was performed on a Cal-
orimetry Sciences Corporation Model 4200 (Provo, UT, USA). Sur-
face plasmon resonance used a Biacore 2000 instrument at the Bio-
polymer Facility of Ohio State University (Columbus, OH, USA).
2.1. Isothermal titration calorimetry (ITC)
Titrations HB-GAM (1 ml at 30.7 WM) with 20 5 Wl injections of
heparin (400 WM) were performed in 50 mM sodium phosphate bu¡-
er, pH 7.4, containing 100 mM NaCl. Experimental details and data
processing relied on previously described methods [17].
2.2. Immobilization of HB-GAM on biocore sensor chip
HB-GAM was covalently bound to the sensor surface via primary
amino groups using the manufacturer’s protocol. Brie£y, the carboxy-
methylated dextran matrix (CM 5% sensor chip) was ¢rst activated
using a 7 min (35 Wl) injection pulse of an equimolar mix of N-hy-
droxysuccinimide (NHS) and N-ethyl-NP-(dimethyaminopropyl) car-
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bodiimide (¢nal concentration is 0.05 M, mixed immediately prior to
injection). A 35 Wl volume of HB-GAM (typically 5 Wg/ml in 5 mM
sodium phosphate bu¡er, pH 7.4) was then £owed over the activated
surface. Excess unreacted sites on the sensor surface were blocked
with a 35 Wl injection of 1 M ethanolamine. 1500 RU of HB-GAM
were immobilized on the sensor chip.
2.3. Kinetic measurements of HB-GAM heparin interactions via surface
plasmon resonance
A 15 Wl injection of heparin, in the concentration range of 100^1000
nM in 50 nM sodium phosphate, pH 7.4, was made at a £ow rate of
5 Wl/min. At the end of the sample plug, the same bu¡er was £owed
over the sensor surface to facilitate dissociation. After a suitable dis-
sociation time, the sensor surface was regenerated for the next sample
using a 10 Wl pulse of 2 M NaCl. The response was monitored as a
function of time (sensorgram) at 25‡C. Kinetic parameters were eval-
uated using the BIA Evaluation software (Pharmacia Biosensor) ac-
cording to manufacturer’s methods by ¢rst evaluating the dissociation
rate constant kd using dR/dt =3kdR where R represents the sensor
response. The association rate constant was determined from the slope
of a plot of the observed association rate constant ks as a function of
ligand concentration, according to ks = kd+kaC where ka is the asso-
ciation rate constant and C represents the ligand concentration. The
dissociation constant, Kd, was obtained from the ratio kd/ka.
2.4. Preparation of HB-GAM-Sepharose
HB-GAM (1 mg) was dissolved in the coupling bu¡er (100 mM
sodium bicarbonate containing 500 mM NaCl, pH 8.4) and injected
onto a 1 ml NHS-activated HiTrap column that had been washed
with cold 1 mM HCl. The column was sealed and allowed to stand
at 4‡C overnight. Deactivation of any excess active groups, which had
not coupled to the ligand, was performed by repeated washings with
3 M ethanolamine, pH 8.6 and 100 mM acetic acid bu¡er containing
1 M NaCl bu¡er at pH 4.5.
2.5. Preparation of oligosaccharides
Heparin (10 g) was digested to 30% reaction completion using hep-
arin lyase I as previously reported [18] and fractionated by Sephadex
G50 gel exclusion chromatography into sized oligosaccharide mix-
tures. A mixture of tetradecasaccharides and higher oligosaccharides,
prepared by repeated gel permeation chromatography [18] and char-
acterized by gradient polyacrylamide gel electrophoresis (PAGE) [19]
was used for a⁄nity chromatography. A single tetradecasaccharide
was puri¢ed from the mixture using strong anion exchange high per-
formance liquid chromatography and its purity was assessed as
s 90% by gradient PAGE [19] and capillary electrophoresis (CE)
[18]. One-dimensional (1D) 1H-NMR and 2D COSY NMR were
used to examine the structure of this tetradecasaccharide [18].
2.6. HB-GAM-Sepharose a⁄nity chromatography of a sized heparin
oligosaccharide mixture
Excess oligosaccharide mixture (500 Wg) was loaded onto the HB-
GAM-Sepharose column, equilibrated with 200 mM NaCl in 5 mM
sodium phosphate at pH 7.4 bu¡er. The column was washed with 10
ml of the same bu¡er and eluted with 30 ml gradient of 0.2 to 2 M
NaCl in sodium phosphate bu¡er, pH 7.4. The eluent was monitored
at 232 nm and salt concentrations were determined by measuring the
conductivity. Fractions corresponding to the interacting peak were
collected and exhaustively dialyzed (1000 molecular weight cut-o¡
membranes) for 4 days against 4U20 l distilled water and lyophilized.
2.7. Polyacrylamide gel electrophoresis
Fractions from the a⁄nity chromatography experiments were ana-
lyzed by gradient PAGE. Samples were dissolved in 10^15 Wl of dis-
tilled water and 15 Wl of a 50% (w/v) sucrose solution and subjected to
electrophoresis on a 20 cm long linear gradient (12 to 22% total
acrylamide) gel for 5 h at 400 V or through a 32 cm long gradient
gel for 18 h at 400 V. The gels were stained with alcian blue (0.5% in
2% acetic acid) for 30 min, destained by washing with distilled water
for 24 h, and silver stained.
3. Results
Isothermal titration calorimetry was used to characterize
the HB-GAM heparin interaction (Fig. 1). This technique
a¡ords vH, Kd and n (the number of ligand interactions per
mole of macromolecule). The ¢tted heats of interaction for
titrations of heparin into HB-GAM yielded a Kd of 460
nM, vH of 330 kcal/mole and an n of 3 moles of
HB-GAM per mole of heparin at 25‡C in 50 mM sodium
phosphate, 100 mM NaCl, pH 7.4. This n corresponds to a
heparin binding site for HB-GAM of 12 to 16 saccharide
residues.
Negatively charged carboxymethylated dextran was selected
as the support on the sensor surface of the plasmon resonance
chip for immobilization of HB-GAM to prevent a favorable
contribution from the surface on the heparin HB-GAM inter-
action being determined. A control experiment demonstrated
no interaction took place between the carboxymethylated dex-
tran coated sensor surface and HB-GAM (not shown). When
HB-GAM was immobilized to the carboxymethylated dextran
on the sensor chip, and heparin £owed over this surface, a
strong interaction was observed (Fig. 2). A ka (on-rate) of
6.6U105 ( þ 8U104) M31 s31 and a kd (o¡-rate) of
2.4U1033 ( þ 1U1033) s31 was observed. The dissociation
rate constant, obtained from multiple traces, was combined
with the slope of the linear portion of the observed association
rate constant as a function of ligand concentration (inset) to
obtain the dissociation constant (Kd) of 4( þ 2) nM. Despite
the negatively charged underlying surface coating of carboxy-
methylated dextran, SPR gave a 100-fold stronger binding
a⁄nity than that measured in solution using ITC.
ITC showed that the minimum binding site in heparin con-
tained 12 to 16 saccharide residues, consistent with the report
that oligosaccharides of 14 saccharide residues gave inhibition
of HB-GAM [14]. A heparin tetradecasaccharide contained in
an interacting mixture was selected and puri¢ed to homoge-
neity by gel permeation chromatography and strong anionic
exchange high pressure liquid chromatography [18]. PAGE
and CE analysis demonstrated this tetradecasaccharide
showed it to be s 90% pure. 1D 1H-NMR and 2D COSY
NMR were used to identify it as a tetradecasaccharide con-
taining an internal antithrombin III binding domain, similar
Fig. 1. Binding isotherm of the interaction between HB-GAM and
heparin. HB-GAM (in the cell) was titrated with heparin (in the sy-
ringe). The heat released a¡orded peaks that were integrated and
the total heat per injection (peak area) are plotted as a function of
injection number.
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to the structure of an analogous decasaccharide of de¢ned
structure previously established by our laboratory [19]. A⁄n-
ity chromatography of this tetradecasaccharide demonstrated
that it bound to a HB-GAM-Sepharose column and eluted at
1 M NaCl (not shown), con¢rming that a tetradecasaccharide
was su⁄ciently large to bind tightly to HB-GAM. Next, the
optimum heparin oligosaccharide size for HB-GAM binding
was examined using a mixture of large oligosaccharides (de-
gree of polymerization (dp) s 14). The column was loaded
with excess oligosaccharide mixture (550 Wg) and eluted with a
salt gradient. Multiple peaks were observed in the run-
through but a single peak was observed eluting at 1.2 M
NaCl (Fig. 3). This peak, containing high a⁄nity oligosac-
charides, was dialyzed and freeze-dried. Analysis by gradient
PAGE showed that this peak contained only very large oligo-
saccharides (dps 18) having the highest a⁄nity for HB-
GAM.
4. Discussion
Previous studies have demonstrated that heparin had high
a⁄nity for HB-GAM and suggested that the heparan sulfate
proteoglycan N-syndecan might be an endogenous ligand [11].
Studies on mixture of heparin derived oligosaccharides
showed that a minimum heparin binding site having 10 sac-
charide residues with optimum binding occurred between 14
and 18 saccharide residues [14]. In the current study, two
di¡erent methods were used to examine heparin interaction
with HB-GAM. ITC is a thermodynamic, solution phase
measurement of the heat of interaction and SPR is a two-
phase kinetic measurement of interaction. Heparin showed a
strong binding a⁄nity to HB-GAM in solution as determined
by ITC but an even stronger binding a⁄nity to HB-GAM
immobilized on a surface as determined by SPR. The di¡er-
ence in the binding constant obtained using these two meth-
ods might be due to the multivalency of HB-GAM and the
cooperative nature of this interaction when measured on a
surface. The size of the minimum binding site within heparin
for HB-GAM was determined to be 14 saccharide units by
ITC. The interaction of a pure tetradecasaccharide with HB-
GAM immobilized on Sepharose con¢rmed the size of the
minimum HB-GAM binding site. Finally, when a mixture of
oligosaccharides of dps 14 were added in excess to this HB-
GAM column only very large oligosaccharides of dps 18
bound, suggesting that these extended sequences represented
an optimal binding domain within heparin. The large size of
this binding domain and the high a⁄nity of this interaction
suggest that both the N-terminal and C-terminal clusters of
basic amino acid residues are involved in this interaction, thus
requiring a long heparin sequence to span these sites.
Fig. 3. A⁄nity chromatography of heparin oligosaccharides on HB-
GAM-Sepharose. Panel A: Absorbance (232 nm) (left axis) plotted
as a function of fraction number (0.8 ml/fraction) shows the elution
of oligosaccharides. The salt concentration (right axis) was measured
by conductivity. Panel B: Gradient PAGE analysis of the oligosac-
charide sample loaded onto the column (lane a) was identical to
that eluting in fraction 5 (not shown). The high a⁄nity oligosac-
charides eluting in fraction 35 (lane b) had an average dp of s 18
as shown by the oligosaccharide markers (lane c, dp labeled on
right).
Fig. 2. SPR sensorgram of HB-GAM heparin interaction. HB-GAM was immobilized onto a sensor chip and di¡erent concentrations of hepa-
rin were £owed over the chip (association phase) followed by bu¡er (dissociation phase). The association phase and the dissociation phase were
used to calculate the Kd. The inset shows the observed association rate as a function of ligand concentration used to calculate the Kd.
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